Floatz logo

Fingolimod

Anaplastic Astrocytoma

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculeEarly Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Anaplastic Astrocytoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2/3BB
Carboplatin
Oliver Jonas
Phase 2BB
gsk1120212
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Fingolimod is also rated in:

relapsing-remitting multiple sclerosisDormant
A
Indicative ·
82 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
cerebral degenerationDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →